Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.58 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.50 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591852 | 0.86 | LMNA (0.62) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL8145365 | 0.81 | HTR1A (0.61) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL2997568 | 0.80 | HTR1A (0.59) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL27809163 | 0.80 | TLR8 (0.62) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL24010334 | 0.79 | HTR1A (0.59) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL28203153 | 0.79 | TLR8 (0.45) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29952206 | 0.79 | HTR1A (0.55) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL11772078 | 0.79 | HTR1A (0.58) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL31298565 | 0.79 | HTR1A (0.58) | TLR8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL201122 | 0.79 | HTR1A (0.58) | TLR8HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874420-B | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-115368301-B | Preparation method of 4-hydroxy-7-methoxyquinoline | 常州琦诺生物科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116874420-A | Preparation method of lenvatinib intermediate 4-chloro-7-methoxyquinoline-6-amide | 山东轩德医药科技有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115368301-A | Preparation method of 4-hydroxy-7-methoxyquinoline | 常州琦诺生物科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-114957114-A | Synthetic method of 4-bromo-3-chloro-7-methoxyquinoline | 冷志 | 2022-08-30 | — | — | CN | claimed |
| CN-111440118-A | New synthesis process of 4-hydroxy-7-methoxyquinoline | 滁州拜奥生物科技有限公司 | 2020-07-24 | — | — | CN | claimed |
| US-20190315770-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2019-10-17 | — | — | US | claimed |
| US-10401747-B1 | Undercoat layer for imaging device | XEROX CORPORATION (US) | 2019-09-03 | — | — | US | claimed |
| EP-3498717-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | The Catholic University of Korea Industry-Academic Cooperation Foundation (KR) | 2019-06-19 | — | — | EP | claimed |
| CN-109790179-A | Composition for hardening soft tissue | 加图立大学校产学协力团 | 2019-05-21 | — | — | CN | claimed |
| CN-121609673-B | PDE4 inhibitor and preparation method and application thereof | WUYI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20250115609-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4472982-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4450503-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | Innovstone Therapeutics Limited (CN) | 2024-10-23 | — | — | EP | disclosed |
| EP-0168309-A1 | Isoxazoloquinolinone derivatives, process and intermediates for their preparation, use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1986-01-15 | — | — | EP | disclosed |
| US-4447435-A | HYPOTENSIVE AGENTS | THE BOOTS COMPANY PLC (GB) | 1984-05-08 | — | — | US | disclosed |
| US-4442109-A | 3-Methylthiomethyl-and 3-methylsulfinylmethyl-4-quinolinones useful for treating hypertension | THE BOOTS COMPANY LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
| US-3931192-A | Process for piperidine intermediates for quinine, quinidine and analogs thereof | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931193-A | ANTIMALARIA, ANTIARRHYTHMIA INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315770-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | PNLIP, AMY2A, RNASE1 | TLR8 794/4885HTR1A 4693/4885ADRA1D 4772/4885 |
| US-20250115609-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | ENPP1, WEE1, ENPP2 | TLR8 4206/4885HTR1A 2109/4885ADRA1D 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.